Global Diabetic Gastroparesis Treatment Market
Global Diabetic Gastroparesis Treatment Market was valued US$ XXMn in 2019 and is expected to grow US$ XX Mnby 2027, at a CAGR of 4.6% during the forecast period.
To know about the Research Methodology :- Request Free Sample Report
The report study has analyzed the revenue impact of COVID-19 pandemic on the sales revenue of market leaders, market followers, and market disrupters in the report, and the same is reflected in our analysis.
Diabetic gastroparesis is delayed gastric emptying relatedto diabetes. The condition occurs in patients suffering from both type-1 and type-2 diabetes and is common in female patients suffering from type-2 diabetes. The disease includes delayed emptying of the stomach leading to a series of symptoms like nausea, vomiting, abdominal bloating, abdominal pain, weight loss, gastroesophageal reflux, spasms of the stomach wall, and heartburn.For example, according to the study, ‘Global Prevalence of Type-2 Diabetes over the forecast period (2019-2027), published by the American Diabetes Association, 500 million people worldwide suffered from type-2 diabetes in 2019.
Easy access to off-label medicines without instructions is expected to boost the growth of the diabetic gastroparesis market. Medications like anti-emetic drugs (oandesteron) are reasonable and easily accessible in developing economies. Also, increasing preference towards OTC medicines to avoid higher expenditures is leading to greater disbursement of drugs through retail pharmacies and drugstores.
Measures to support product approval and labeling claims for diabetic gastroparesis treatments are expected to offer profitable growth opportunities for a producer in the global diabetic gastroparesis treatment market. For instance, in Feb 2019, a team of researchers associated with Boston Therapeutics, Inc. stated that the Diabetic Gastroparesis Symptom Severity Diary can be a reliable and valid measure that can be used to derive endpoints to estimate treatment benefit in future diabetic gastroparesis interventional trials.
Initiatives of regulatory bodies to issue guidance for the development of drugs for the treatment of diabetic gastroparesis are also expected to supportthe growth of the diabetic gastroparesis treatment market. For example, in Aug 2019, the U.S. FDA issued guidance that reports FDA’s current referencesabout clinical trial designs and clinical endpoint assessments to support the development of drugs for the treatment of idiopathic and diabetic gastroparesis.
The absence of clinical evidence on upgrading offered by prescription drugs is expected to hamperthe growth of the global diabetic gastroparesis treatment market. Metoclopramide, domperidone, and erythromycin are used for the treatment of diabetic gastroparesis. On the other hand, approvals of these drugs are inconsistent across countries, leading to the absence of accessibility of consistent patient progress data because ofthe administration of these drugs.
There are very few drugs in the pipeline, which have the potential for the treatment of diabetic gastroparesis. This is mainly due to the early termination of clinical trials or the failure of drugs to meet statistically important endpoints. Such as, in Aug2018, Dartmouth-Hitchcock Medical Center terminated the randomized, double-blind, placebo-controlled trial of promethazine for treatment of diabetic gastroparesis, conducted in collaboration with the American College of Gastroenterology, because ofa shortage of recruitment.
Region-wise, the global diabetic gastroparesis treatment market has been segmented into Latin America, North America, Europe,Asia Pacific, the Middle East, and Africa. The diabetic gastroparesis treatment market in North America is expected to hold the largest market share of the total market in the future. This is mainly because of advancements in the diabetic care sector of the US.
The objective of the report is to present a comprehensive analysis of the Global Diabetic Gastroparesis Treatment Marketincluding all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers, and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers.
The report also helps in understanding Global Diabetic Gastroparesis Treatment Marketdynamics, structure by analyzing the market segments and project the Global Diabetic Gastroparesis Treatment Marketsize. Clear representation of competitive analysis of key players By Therapeutics, price, financial position, product portfolio, growth strategies, and regional presence in the Global Diabetic Gastroparesis Treatment Marketmake the report investor’s guide.
Scope of the Global Diabetic Gastroparesis Treatment Market: Inquire before buying
Global Diabetic Gastroparesis Treatment Market, By Indication Type
• Compensated Gastroparesis
• Gastric Failure
Global Diabetic Gastroparesis Treatment Market, By Treatment
• Medication
• Surgery
Global Diabetic Gastroparesis Treatment Market, By Drugs
• Gastroprokinetic Agents
o Metoclopramide
o Pruclopride
• Antiemetic Agents
o Prochlorperazine
o Ondansetron
• Botulinum Toxin
• Others
Global Diabetic Gastroparesis Treatment Market, By Route of Administration
• Oral
• Injectable
Global Diabetic Gastroparesis Treatment Market, By End Users
• Hospitals
• Homecare
• Specialty Clinics
• Others
Global Diabetic Gastroparesis Treatment Market, By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Others
Global Diabetic Gastroparesis Treatment Market, By Region
• North America
• Europe
• Asia Pacific
• Middle East & Africa
• South America
Key players operating in the Global Diabetic Gastroparesis Treatment Market
• Theravance Biopharma
• Allergan
• GlaxoSmithKline plc
• Endologic
• Evoke Pharma
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Vanda Pharmaceuticals
• F. Hoffmann-La Roche Ltd
• CINRX
• Ironwood Pharmaceuticals, Inc
• ANI Pharmaceuticals, Inc
• Bausch Health
• RHYTHM PHARMACEUTICALS, INC
• Teva Pharmaceutical Industries Ltd
• WOCKHARDT
• Fresenius Kabi AG
• Pfizer Inc
• Ipca Laboratories Ltd
• Vintage Labs
• Others
For More Information Visit @:https://www.maximizemarketresearch.com/market-report/global-diabetic-gastroparesis-treatment-market/79818/
This Report Is Submitted By : Maximize Market Research Company
Customization of the report:
Maximize Market Research provides free personalized of reports as per your demand. This report can be personalized to meet your requirements. Get in touch with us and our sales team will guarantee provide you to get a report that suits your necessities.
About Maximize Market Research:
Maximize Market Research provides B2B and B2C research on 20,000 high growth emerging opportunities & technologies as well as threats to the companies across the Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.
Comments
0 comment